Gyre Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is GYRE moving today?
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for GYRE.
GYRE insider activity
Gyre Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for GYRE.
GYRE contract awards, year to date.
Public federal awards linked to this ticker.
GYRE lobbying filings, year to date.
Registered lobbying filings matched to Gyre Therapeutics, Inc. Common Stock.